+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review

  • ID: 1322621
  • SWOT Analysis
  • 44 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Allergan Ltd
  • Aristo Pharma GmbH
  • F. Hoffmann-La Roche Ltd
  • Geistlich Pharma AG
  • Genentech Inc
  • Labatec Pharma SA
  • MORE
Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

Key Information Included
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company’s lead sealant product is Neuroseal. The company operates in Schlieren, Switzerland; Bilthoven, the Netherlands; Burlington, USA and in Konstanz, Germany. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG Key Recent Developments

Jul 24, 2019: Kuros announces Gerhard Ries is stepping down as Board member
Apr 30, 2019: Kuros Biosciences to propose re-appointment of chairman and board members at Annual General Meeting
Apr 12, 2019: Kuros Biosciences reports results for the full year 2018
Dec 17, 2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track
Sep 05, 2018: Kuros Biosciences announces results for first half 2018

Key Benefits

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Ltd
  • Aristo Pharma GmbH
  • F. Hoffmann-La Roche Ltd
  • Geistlich Pharma AG
  • Genentech Inc
  • Labatec Pharma SA
  • MORE
Section 1 - About the Company
  • Kuros Biosciences AG - Key Facts
  • Kuros Biosciences AG - Key Employees
  • Kuros Biosciences AG - Key Employee Biographies
  • Kuros Biosciences AG - Major Products and Services
  • Kuros Biosciences AG - History
  • Kuros Biosciences AG - Company Statement
  • Kuros Biosciences AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Kuros Biosciences AG - Business Description
  • R&D Overview
  • Kuros Biosciences AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Kuros Biosciences AG - Strengths
  • Kuros Biosciences AG - Weaknesses
  • Kuros Biosciences AG - Opportunities
  • Kuros Biosciences AG - Threats
  • Kuros Biosciences AG - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Kuros Biosciences AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Jul 24, 2019: Kuros announces Gerhard Ries is stepping down as Board member
  • Apr 30, 2019: Kuros Biosciences to propose re-appointment of chairman and board members at Annual General Meeting
  • Apr 12, 2019: Kuros Biosciences reports results for the full year 2018
  • Dec 17, 2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track
  • Sep 05, 2018: Kuros Biosciences announces results for first half 2018
  • Aug 23, 2018: Kuros Biosciences names Pascal Longlade as chief medical officer
  • May 31, 2018: Kuros Biosciences to Propose Appointment of New Board Members at AGM
  • Apr 30, 2018: Kuros Biosciences Reports Full-Year 2017 Results
  • Mar 12, 2018: Kuros Biosciences obtains European patent covering osteoinductive materials
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • Kuros Biosciences AG, Key Facts
  • Kuros Biosciences AG, Key Employees
  • Kuros Biosciences AG, Key Employee Biographies
  • Kuros Biosciences AG, Major Products and Services
  • Kuros Biosciences AG, History
  • Kuros Biosciences AG, Subsidiaries
  • Kuros Biosciences AG, Key Competitors
  • Kuros Biosciences AG, Ratios based on current share price
  • Kuros Biosciences AG, Annual Ratios
  • Kuros Biosciences AG, Interim Ratios
  • Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Kuros Biosciences AG, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Kuros Biosciences AG, Performance Chart (2014 - 2018)
  • Kuros Biosciences AG, Ratio Charts
  • Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novartis AG
  • Medicopharm AG
  • Labatec Pharma SA
  • Genentech Inc
  • Geistlich Pharma AG
  • F. Hoffmann-La Roche Ltd
  • Aristo Pharma GmbH
  • Allergan Ltd
Note: Product cover images may vary from those shown
Adroll
adroll